What does Inmune Bio, Inc. (INMB) do?

Inmune Bio, Inc. (INMB) is a publicly traded company in the Healthcare sector.

What sector does INMB operate in?

Inmune Bio, Inc. operates in the Healthcare, specifically within the Biological Products, (No Diagnostic Substances) industry. AlphaOS tracks cycle stage, supply-chain relationships, and investment intelligence for companies across all sectors.

Where can I find INMB earnings analysis?

AlphaOS publishes an earnings intelligence page for Inmune Bio, Inc. (INMB) covering results, guidance context, and AI-assisted analysis. See /stocks/INMB/earnings. Content is for research and education — not investment advice.

Intelligence coverage: 60%

Basic profile, financials, and market data are shown below. Deep research is building in the background.

INMB

Inmune Bio, Inc.

Healthcare · Biological Products, (No Diagnostic Substances)

$2.00Sep 28, 2026

AI confidence 70% · prior close shown (market closed)

Investment Snapshot

Weak evidence · 1 source

Why it matters

Inmune Bio, Inc. shows accelerating business momentum based on AlphaOS pipeline evidence.

TrajectoryAccelerating

3 signals not yet derived from pipeline evidence

Pipeline evidence · 22d ago

INMB's AlphaOS Signals

Upgrade to Pro for validated historical pattern analysis on INMB.

Create free account

Free accounts see more of this; Premium sees all of it.

Latest earnings · Q1 2025

Full INMB earnings analysis

Reported figures for Inmune Bio, Inc. — research only, not investment advice.

Revenue YoY: +257.1%

Latest Intelligence

Updated September 28, 2026

What happened recently for Inmune Bio, Inc. (INMB) — events, not interpretation.

Event: Reported Q1 2025 revenue +257% YoY.
Also: Last session September 28, 2026 at $2.
Source: Q1 2025 earnings

Research & analysis only — not investment advice.

Loading earnings intelligence…

Inmune Bio, Inc. (INMB)

Healthcare · Biological Products, (No Diagnostic Substances)

Investment Snapshot above is the primary AlphaOS analysis for Inmune Bio, Inc. — structured signals and evidence from proprietary pipelines, not an encyclopedia overview.

Key facts

Sector:: Healthcare
Industry:: Biological Products, (No Diagnostic Substances)
Market cap:: $55.51M
Revenue:: $50,000

INMB earnings analysis

Research & analysis only — not investment advice. Price, charts, and filings are above.

Connected intelligence

Follow Inmune Bio, Inc. through AlphaOS's knowledge graph — themes, peers, beneficiaries, earnings, and research answers.

Connected companies and research pages from the AlphaOS knowledge graph.